Aderis Pharmaceuticals to Present at UBS Warburg Global Life Sciences Conference.Business Editors & Health/Medical Writers BIOWIRE2K HOPKINTON, Mass.--(BUSINESS WIRE)--Oct. 7, 2002 Company Comments on the Release of Preliminary Findings of Phase II Trial of Rotigotine CDS in Restless Legs Syndrome Restless Legs Syndrome Definition Restless legs syndrome (RLS) is characterized by unpleasant sensations in the limbs, usually the legs, that occur at rest or before sleep and are relieved by activity such as walking. Completed by Schwarz Pharma AG Aderis Pharmaceuticals announced today that Chairman, President and Chief Executive Officer, Peter Savas, will present a corporate overview and clinical trial update on Tuesday, October 8 at 8:30 a.m. (EST EST electroshock therapy. EST abbr. electroshock therapy ) during the UBS UBS Union Bank of Switzerland UBS United Bible Societies UBS United Blood Services UBS United Buying Service UBS Used Bookstore UBS University Business Services UBS Universal Building Society (UK) UBS Ulaanbaatar Broadcasting System Warburg Global Life Sciences Conference. Aderis Pharmaceuticals has four product candidates currently in clinical development for five indications. These include the Company's lead product candidate, Rotigotine CDS, which is currently in Phase III clinical trials for treatment of Parkinson's disease Parkinson's disease or Parkinsonism, degenerative brain disorder first described by the English surgeon James Parkinson in 1817. When there is no known cause, the disease usually appears after age 40 and is referred to as Parkinson's disease. and Phase II clinical trials for treatment of Restless Legs Syndrome. Preliminary analyses of data from the Phase II trial of Rotigotine CDS in Restless Legs Syndrome being conducted by Schwarz Pharma AG indicate that treatment with Rotigotine resulted in a significant, dose-related improvement in symptoms. Full analysis of the dataset is ongoing. Schwarz Pharma will report final analysis in November at the 7th International Congress of Parkinson's Disease and Movement Disorders Movement Disorders Definition Movement disorders are a group of diseases and syndromes affecting the ability to produce and control movement. Description in Miami. Restless Legs Syndrome is a neurological disorder Noun 1. neurological disorder - a disorder of the nervous system nervous disorder, neurological disease disorder, upset - a physical condition in which there is a disturbance of normal functioning; "the doctor prescribed some medicine for the disorder"; that often results in moderate to severe sleep deprivation sleep deprivation Sleep disorders A prolonged period without the usual amount of sleep. See Driver fatigue, Poor sleeping hygiene, Sleep disorders, Sleep-onset insomnia. . It is estimated to affect up to 12 million Americans. Today there are no approved therapies for this indication. A recording of Aderis Pharmaceuticals' presentation at the conference will be available until November 10, 2002 through the UBS Warburg web site at www.ubswarburg.com. To access this recording, click on the "events and conferences" link in the lower right hand side of the page and follow the link for Webcast under the Global Life Sciences Conference heading. Aderis Pharmaceuticals is a biopharmaceutical company engaged in small molecule drug development to treat central nervous system, cardiovascular and renal disorders. The Company currently has four product candidates for five indications in development, with one in Phase III clinical trials, three in Phase II clinical trials and one that recently concluded its first Phase I clinical trial Noun 1. phase I clinical trial - a clinical trial on a few persons to determine the safety of a new drug or invasive medical device; for drugs, dosage or toxicity limits should be obtained phase I . Aderis Pharmaceuticals has a strategic alliance with Schwarz Pharma, which is enrolling Phase III clinical trials for the Company's lead product candidate, a dopamine agonist for the treatment of Parkinson's disease using a proprietary continuous delivery transdermal patch transdermal patch: see skin patch. . The Company also has alliances with Fujisawa Healthcare, Inc. and King Pharmaceuticals. Aderis Pharmaceuticals' product pipeline includes receptor agonists and antagonists for the diagnosis and treatment of neurological, cardiovascular and renal diseases. Founded in 1994, Aderis Pharmaceuticals is headquartered in Hopkinton, Massachusetts and has research facilities in Richmond, Virginia. Certain statements in this news release that are not historical fact constitute "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results of Aderis Pharmaceuticals to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors, such as regulatory approvals, collaboration agreements, competition and dependence on senior management, are discussed under the caption "Risk Factors" in Aderis Pharmaceuticals' Form S-1 on file with the Securities and Exchange Commission. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion